Sai-Hong Ignatius Ou
@oncooulungca
ID: 709267635779665921
14-03-2016 06:39:16
106 Tweet
1,1K Takipçi
90 Takip Edilen
Critical Review in Oncology Hematology. Figures to argue for using Lorlatinib as 1L treatment of advanced ALK+NSCLC. Open access. ALK+ International ALK Positive PMID:37187318.
